6078 (6078) Fair Value & Analysis

Healthcare · Market cap HK$5.7B

6 6078 6078 · HK

PriceHK$9.41

Fair ValueHK$9.04

Upside-3.9%

Quality45/100

Watch 6078 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$6.80 – HK$9.46

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −5.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$8.16 – HK$17.98 · fair‑value band HK$6.80 – HK$9.46 · the HK$9.41 price screens above the HK$9.04 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6078 (6078) currently trades at HK$9.41, while our model-based Fair Value estimate is HK$9.04 — implying the stock looks roughly 3.9% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6078 generated revenue of HK$4.0B at a net margin of 4.1%. Revenue declined 2.2% year over year. It earns a return on equity of 2.4%. Net debt stands at HK$2.0B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$4.0B

Revenue growth (YoY) -2.2%

Net margin 4.1%

Return on equity 2.4%

Free cash flow HK$466M FY2025

P/E ratio 30.4

More key figures

Operating margin 16.5%

EPS (TTM) HK$0.4000

EPS growth (YoY) -34.4%

Net debt HK$2.0B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6078 reported revenue of HK$4.0B in FY2025 versus HK$2.3B in FY2021, a compound +14.7%/yr. Reported net income was HK$165M in FY2025, compounding −21.9%/yr from FY2021.

Revenue +14.7%/yr

FY21 HK$2.3B

FY22 HK$3.2B

FY23 HK$4.1B

FY24 HK$4.4B

FY25 HK$4.0B

Net income −21.9%/yr

FY21 HK$441M

FY22 HK$477M

FY23 HK$683M

FY24 HK$598M

FY25 HK$165M

Is 6078 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6078 (6078) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$9.04 versus a price of HK$9.41 — about −4% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6078?

Our model-based fair value for 6078 is HK$9.04 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$9.41.

What is the quality score of 6078?

6078 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6078 (6078)?

6078 reported trailing-twelve-month revenue of about HK$4.0B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6078?

The net profit margin of 6078 is about 4.1%, meaning it keeps roughly 4.1% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.